Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


New Consortium announces Significant Grant Funding of Anaemia product programme


Oxford and London, UK, 12 February 2008. GlycoForm Ltd, PolyTherics Ltd, and Aston University today announced that they have been awarded prestigious grants totalling £685,000 from the Technology Strategy Board and Biotechnology and Biological Sciences Research Council. This consortium is to use this additional funding over the next two years to accelerate the development of a treatment for anaemia initiated by GlycoForm.

Through combining the sugar synthesis and conjugation technology of GlycoForm, the unique PEGylation expertise of PolyTherics and Aston University’s yeast expression capability, the consortium will explore the development of next generation products for the treatment of anaemia. A product with an improved safety profile and an extended half-life is in increasing demand in this £5 billion market.

Michael Short, GlycoForm’s CEO, commented: “We are delighted that this peer reviewed funding will enable us to further accelerate our lead therapeutic product programme for the treatment of anaemia with such an outstanding consortium. This fits well with our existing collaborative programmes of drug modification with sugars to improve treatments for patients”.

Keith Powell, PolyTherics’ CEO, said: “This collaboration complements PolyTherics’ strategy of leveraging our proprietary technologies into best in class bio-therapeutics. Through our existing partnerships, we are already exploring the benefits that come from targeted, controlled modulation of protein half-life. We anticipate being able to apply our capabilities with equal impact to the goals of this new consortium”.

- ENDS -
Editors Notes
Press enquiries to: Margaret Henry, PR Consultant, PolyTherics
Tel: +44 (0)1865 811199 Email: m.henry@oxin.co.uk

About GlycoForm Ltd
GlycoForm is a biopharmaceutical company applying its expertise and technologies in expression, modification and conjugation to produce Novel Synthetic Glycoproteins as products that can make improvements to seriously ill patients’ lives.
GlycoForm has a world leading capability in the synthesis of complex branched human oligosaccharides, GlycoChem, and has developed a range of approaches to conjugate sugars and proteins, including GlycoSeS. These conjugated oligosaccharides can be enzymatically extended to improve pharmacokinetic properties, GlycoExtend.

GlycoForm is a privately held company based in Milton Park, Oxford, UK and was established as a spin-out of Oxford University in 2002.

GlycoForm has a stepwise business model. Firstly it is anchoring the value of the platform by developing in-house programmes. These products will be improvements to well established drugs where there is a clear unmet clinical need and the current market value is significant. These data will be used to support the development of the collaborative programmes. Here mutual benefit will be derived for both parties while the new intellectual property generated around the underlying Company expertise will remain GlycoForm’s. This approach will give the Company access to a range of new therapeutic proteins and will build significant value and credibility in the platform. These data sets will then be used to support commercial partnerships.
For further information: www.glycoform.co.uk

About PolyTherics Ltd
Founded in 2002, PolyTherics is a spin-out company from Imperial College London and the London School of Pharmacy that is dedicated to using biomedical polymers to optimise pharmaceuticals for the treatment and cure of the world's most important diseases.

PolyTherics has developed and patented an innovative approach to PEGylation, known as TheraPEG™, to prolong the half-life of proteins for use in drug development. PEGylation is the process by which Polyethylene Glycol (PEG) is attached to proteins and peptides to modify their pharmacokinetic properties for therapeutic application.

PEGylation increases the time that a compound remains in the bloodstream before being meta


Publisher Contact Information:

PolyTherics, Ltd.
+44 (0)1865 811199
m.henry@oxin.co.uk

Company profile of PolyTherics, Ltd.
Past press releases of PolyTherics, Ltd. .

Data


27,742
Tech investments
From our Online Data Service
17,891
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.